| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 2,386,244 | 2,753,963 | ||
| General and administrative | 1,976,335 | 1,969,828 | ||
| Total operating expenses | 4,362,579 | 4,723,791 | ||
| Loss from operations | -4,362,579 | -4,723,791 | ||
| Other income (expenses) | 248 | - | ||
| Other expenses | - | 0 | ||
| Write off of deferred offering costs | 500,000 | - | ||
| Interest income (expense), net | 5,936 | 13,776 | ||
| Change in fair value of earnout and derivative liabilities | - | 0 | ||
| Stock-based inducement expense | - | 707,300 | ||
| Gain from settlement of liabilities with vendors | - | 0 | ||
| Total other income (expenses), net | -493,816 | -693,524 | ||
| Net loss | -4,856,395 | -5,417,315 | ||
| Deemed dividend on series a, b and c preferred stock | - | 24,700,374 | ||
| Deemed dividend related to series c common warrants | - | 0 | ||
| Deemed dividend on series d preferred stock | 6,649,828 | - | ||
| Net loss attributable to common shareholders | -11,506,223 | -30,117,689 | ||
| Basic (in dollars per share) | -9.1 | -61.71 | ||
| Basic (in shares) | 1,264,884 | 488,076 | ||
| Diluted (in dollars per share) | -9.1 | -61.71 | ||
| Diluted (in shares) | 1,264,884 | 488,076 | ||
CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CERO THERAPEUTICS HOLDINGS, INC. (CERO)